These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 8210642)
81. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples. Teichmann JV; Ludwig WD; Thiel E Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400 [TBL] [Abstract][Full Text] [Related]
82. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932 [TBL] [Abstract][Full Text] [Related]
83. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943 [TBL] [Abstract][Full Text] [Related]
84. Susceptibility of human leukemia cells to allogeneic and autologous lymphokine-activated killer cells and its augmentation by exposure of leukemia target cells to cytotoxic drugs in vitro and in vivo. Teichmann JV; Ludwig WD; Thiel E Recent Results Cancer Res; 1993; 131():223-38. PubMed ID: 8210642 [No Abstract] [Full Text] [Related]
85. Role of interleukin-2 activated MHC-nonrestricted lymphocytes in antileukemia activity and therapy. Lotzová E Leuk Lymphoma; 1992 May; 7(1-2):15-28. PubMed ID: 1472926 [TBL] [Abstract][Full Text] [Related]